Compare Shell PLC (SHEL) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Tempus AI — how do they compare? Shell PLC trades at $100.22 (market cap $284.34B), while Tempus AI trades at $70.4 (market cap $12.58B). The key difference: Shell PLC is far larger — about 22.6× Tempus AI's market cap, and Shell PLC pays a 3.12% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 90 Days and Tempus AI for 22 Days on average.
| SHEL | TEM | |
|---|---|---|
Market Cap | $284.34B | $12.58B |
Volume | 9,097,469 | 7,444,569 |
Sector | Energy | Broad Market / Factor |
52-Week High | $100.20 | $99.28 |
52-Week Low | $70.31 | $41.55 |
Typical Hold Time | 90 Days | 22 Days |
Enterprise Value | $326.04B | $13.21B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $96.85, down 0.79% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company's valuation ratios are attractive, with a P/E of 11.08 and P/S of 0.97, while profitability metrics like a 14.35% ROE and 8.76% net margin reflect solid fundamentals. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, positioning Shell for long-term growth in energy transition markets.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, but risks involve volatile oil prices and execution challenges in new projects. The stock offers value with upside potential, though investors should monitor energy market dynamics and debt levels.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
